Tianjin Pharmaceutical Da Ren Tang's (SGX:T14, SHA:600329) net profit attributable to owners of the parent declined 3% during the first quarter of the year to 374.2 million yuan from 387.3 million yuan a year earlier, according to a filing with the Singapore Exchange on Tuesday.

Earnings per share dropped to 0.49 yuan compared with 0.50 yuan in the comparable period.

Revenue declined 30% year over year to 1.46 billion yuan from 2.09 billion yuan, due to a change in the consolidation scope which excluded data from Tianjin Zhongxin Medicine.